Soligenix
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1987-01-01
- Employees
- 15
- Market Cap
- $8.8M
- Website
- http://www.soligenix.com
- Introduction
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Confirmatory Study of Topical HyBryteâ„¢ Vs. Placebo for the Treatment of CTCL
- Conditions
- Mycosis FungoidesCutaneous T Cell LymphomaCTCL/ Mycosis FungoidesCTCL
- Interventions
- Drug: PlaceboDrug: Hypericin
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 80
- Registration Number
- NCT06470451
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
Dusquetide for the Treatment of Behcet's Disease
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 25
- Registration Number
- NCT06386744
- Locations
- 🇹🇷
Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
- Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 10
- Registration Number
- NCT06149247
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States
Topical SGX302 for Mild-to-Moderate Psoriasis
- Conditions
- Plaque PsoriasisPsoriasisPsoriasis Vulgaris
- Interventions
- Drug: HypericinDrug: Placebo
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 47
- Registration Number
- NCT05442190
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 9
- Registration Number
- NCT05380635
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity and OropharynxOral Mucositis
- Interventions
- Drug: SGX942Drug: Placebo
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 266
- Registration Number
- NCT03237325
- Locations
- 🇫🇷
CROM-Osny, Osny, France
🇺🇸Hackensack Meridian Health, Neptune, New Jersey, United States
🇫🇷Clinique Victor Hugo, Le Mans, France
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
- Conditions
- Cutaneous T-Cell Lymphoma
- Interventions
- Drug: SGX301 (synthetic hypericin)Drug: Placebo
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 169
- Registration Number
- NCT02448381
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Olympian Clinical Research, Clearwater, Florida, United States
🇺🇸Leon Medical Research, Miami, Florida, United States
A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer
- Conditions
- Oral Mucositis
- Interventions
- Drug: PlaceboDrug: SGX942
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 111
- Registration Number
- NCT02013050
- Locations
- 🇺🇸
Markey Cancer Center-University of Kentucky, Lexington, Kentucky, United States
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
- Conditions
- Chronic Gastrointestinal Graft vs Host Disease
- Interventions
- Drug: orBecDrug: Placebo
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 2
- Registration Number
- NCT01925950
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
- Conditions
- Enteritis
- Interventions
- Drug: SGX201 (delayed release beclomethasone 17,21-dipropionate)
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 16
- Registration Number
- NCT01073384
- Locations
- 🇺🇸
Boston University, Boston, Massachusetts, United States
🇺🇸Northwestern University Medical Center, Chicago, Illinois, United States